Arcutis Biotherapeutics Acquires Ducentis BioTherapeutics Ltd.

Novartis Acquires Cadent Therapeutics

December 17, 2020

Biotechnology

Novartis has entered an agreement to acquire Cadent Therapeutics, a Cambridge, Massachusetts–based clinical‑stage neuroscience company, adding two clinical‑stage programs for schizophrenia and movement disorders plus the buyout of MIJ821 milestones/royalties. The deal (reported up to $770 million including milestones) strengthens Novartis' neuropsychiatry portfolio and is expected to close in Q1 2021 subject to customary conditions.

Novartis Acquires DTx Pharma

July 17, 2023

Biotechnology

Novartis has acquired DTx Pharma, a San Diego–based preclinical biotechnology company, for an upfront payment of USD 500 million plus contingent milestone payments. The deal brings DTx's FALCON siRNA delivery platform and lead program DTx-1252 (orphan-designated for CMT1A) into Novartis to strengthen its neuroscience pipeline and xRNA capabilities.

BioNTech Acquires Biotheus

February 3, 2025

Biotechnology

BioNTech SE has completed the acquisition of clinical-stage biotechnology company Biotheus for $800 million in cash and ADS consideration plus up to $150 million in milestone payments. The deal gives BioNTech full global rights to BNT327 and Biotheus' antibody platform, and adds a local R&D hub and biologics manufacturing facility in China to BioNTech's network to support its oncology strategy.

Bausch Health Acquires DURECT Corporation

September 11, 2025

Biotechnology

Bausch Health Companies Inc. completed a tender offer to acquire DURECT Corporation for $1.75 per share in cash (approximately $63 million upfront), plus up to $350 million in potential net sales milestone payments. The acquisition brings DURECT’s lead asset, larsucosterol — an FDA Breakthrough Therapy candidate for alcohol-associated hepatitis with a Phase 3 program planned — into Bausch Health’s hepatology pipeline; DURECT will become a wholly owned subsidiary and its Nasdaq shares will be delisted.

BioDerm (Mountaingate) Acquires Argentum Medical

February 1, 2023

Medical Devices

BioDerm, a portfolio company of Mountaingate Capital, has acquired Argentum Medical and combined the business with BioDerm to create a larger wound-care and infection-prevention platform. Mountaingate supported the combination through its existing ownership of BioDerm and new investment in the combined entity, with Five Points Capital providing unitranche financing to support the refinancing and acquisition; Shore Capital Partners sold Argentum.

Dovetail Genomics and Arc Bio Merge to Form Cantata Bio

June 6, 2022

Biotechnology

Dovetail Genomics and Arc Bio have merged under the ownership of EdenRoc Sciences to launch Cantata Bio, a life‑sciences tools company focused on multimodal NGS-based products and services. The combined company will offer three business units (Epigenetics & Genome Structure, Microbial Profiling, and Genetic Analysis Solutions) and has launched the Dovetail TopoLink Kit to accelerate genomic interaction capture workflows.